Dr. Carolyn Crandall's research focuses on the intersection between breast cancer, menopause and osteoporosis. She has evaluated associations between menopausal hormone therapy and breast cancer risk as well as associations between breast tenderness during menopausal hormone therapy and changes in mammographic density. She is particularly interested in the effects of breast cancer and its therapy on menopausal symptoms and osteoporosis (bone density and fracture risk).
Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, Shifren J, Chen C, Kaunitz AM, Cauley JA, Manson JE. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause. 2017 Aug 14. doi: 10.1097/GME.0000000000000956. [Epub ahead of print]
Crandall CJ, Aragaki AK, Cauley JA, McTiernan A, Manson JE, Anderson G, Chlebowski RT. Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials. Breast Cancer Res Treat. 2012 Feb;132(1):275-85. doi: 10.1007/s10549-011-1848-9. Epub 2011 Nov 1.
Crandall CJ, Aragaki AK, Cauley JA, McTiernan A, Manson JE, Anderson GL, Wactawski-Wende J, Chlebowski RT. Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. Breast Cancer Res Treat. 2012 Feb;131(3):969-79. doi: 10.1007/s10549-011-1803-9. Epub 2011 Oct 7.
Crandall CJ, Markovic D, Huang MH, Greendale GA. Predictors of breast discomfort among women initiating menopausal hormone therapy. Menopause. 2010 May-Jun;17(3):462-70. doi: 10.1097/gme.0b013e3181c29e68
Crandall CJ, Aragaki AK, Chlebowski RT, McTiernan A, Anderson G, Hendrix SL, Cochrane BB, Kuller LH, Cauley JA. New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk. Arch Intern Med. 2009 Oct 12;169(18):1684-91. doi: 10.1001/archinternmed.2009.303.